The phase II clinical study of the first batch of population officially launched on June 20 will further evaluate the immunogenicity and safety of the vaccine in the healthy population, and determine the immunization procedures and doses.
According to the previous report, the phase I / II clinical trial of the new coronavirus inactivated vaccine developed by Wuhan Institute of biological products of China biology was unblinded. The results showed that the vaccinators in the vaccine group all produced high titer antibodies; there was no serious adverse reaction; the positive rate of antibody in the two doses of 0,28 day routine vaccination in the 18-59 age group reached 100%. This is also the first phase I / II clinical study of a new inactivated coronavirus vaccine in the world
In addition, according to the notice of the Ministry of science and technology and the national health and Health Commission on June 19, the research team of China has arranged 12 vaccine research and development tasks according to five technical routes, including inactivated vaccine, recombinant subunit vaccine of genetic engineering, adenovirus vector vaccine, attenuated influenza virus vector vaccine and nucleic acid vaccine. At present, clinical trials have been carried out on one adenovirus vector vaccine and four inactivated vaccines, accounting for 40% of the total number of clinical trials in the world.